A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti‐melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma.

[1]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Steven W. Johnson,et al.  Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial , 2004 .

[3]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[4]  P. Richardson.  Clinical update: proteasome inhibitors in hematologic malignancies. , 2003, Cancer treatment reviews.

[5]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Sakamoto.  Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. , 2002, Molecular genetics and metabolism.

[7]  J. Adams.  Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. , 2002, Current opinion in chemical biology.

[8]  S. Soignet,et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  D. Schenkein.  Proteasome inhibitors in the treatment of B-cell malignancies. , 2002, Clinical lymphoma.

[10]  C. Wójcik.  Regulation of apoptosis by the ubiquitin and proteasome pathway , 2002, Journal of cellular and molecular medicine.

[11]  J. Adams,et al.  Proteasome inhibition in cancer: development of PS-341. , 2001, Seminars in oncology.

[12]  H. Withers,et al.  Molecular Pathways That Modify Tumor Radiation Response , 2001, American journal of clinical oncology.

[13]  R. Bold,et al.  Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. , 2001, The Journal of surgical research.

[14]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[15]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[16]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[17]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[19]  Marc W. Kirschner,et al.  How Proteolysis Drives the Cell Cycle , 1996, Science.

[20]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[21]  B. Zetter,et al.  Adhesion molecules in tumor metastasis. , 1993, Seminars in cancer biology.

[22]  P. O'dwyer,et al.  Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Plemper,et al.  Protein degradation in human disease. , 2002, Progress in molecular and subcellular biology.

[24]  S. Gillessena,et al.  The Proteasome , a New Target for Cancer Therapy , 2002 .

[25]  P. Elliott,et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. , 2001, International journal of radiation oncology, biology, physics.

[26]  A. Goldberg,et al.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.